The round was led by Taikang Investment through Shandong State-owned Taikang Industry Development Fund (Taikang) with participation from Sequoia China, and H&Q Asia Pacific.
The company intends to use the funds to advance the development of EOC’s mid- and late-stage clinical pipeline, and to in-license additional late-stage oncology assets to bring new treatment options to patients in China.
Led by Dr. Xiaoming Zou, Founder and CEO, EOC Pharma is dedicated to rapidly developing and commercializing innovative global oncology products in China. The company currently has a broad portfolio of drug candidates, including two innovative small molecule products expected to enter Phase 3 registration studies in China in 2018 for the treatment of breast cancer and gastric cancer, respectively.
Its pipeline also includes innovative biologics being developed for indications in immuno-oncology and tumor metastasis.